Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma.
The surgical specimens from 51 men submitted to radical prostatectomy for localized prostate cancer were examined by immunohistochemistry using proliferation cell nuclear antigen (PCNA) monoclonal antibody to evaluate the proliferative index (PI). The relationship between PI, biological variables and p53 protein expression was evaluated by immunohistochemistry. PI was low in invasive localized prostate carcinoma (mean, 12.4%) and the incidence of PCNA-positive cells was significantly higher in tumors with p53 expression (P = 0.0226). There was no statistical difference in PCNA values when biological parameters such as Gleason score, tumor volume, extraprostatic involvement, seminal vesicle infiltration or lymph node metastasis were considered. We conclude that proliferative activity is usually low in prostate carcinoma but is correlated with p53 immune staining, indicating that p53 is important in cell cycle control in this neoplasm.
Leite
K R
KR
Laboratório de Patologia Cirúrgica e Molecular, Hospital Sírio Libanês, São Paulo, Brasil. ramosk@ibm.net
Srougi
M
M
Nesralhah
L J
LJ
Camara-Lopes
L H
LH
D000368:Aged; D002277:Carcinoma / Q000235:genetics / Q000473:pathology*; D002455:Cell Division; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*
D018809:Proliferating Cell Nuclear Antigen